Slingshot members are tracking this event:
England's National Institute for Health and Care Excellence (NICE) Recommends Celgene's (CELG) Otezla for Approval to Treat Adult Patients with Active Psoriatic Arthritis
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Dec 22, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Nice, Otezla, Adult Patients, Active Psoriatic Arthritis